StemCell Therapy

NEW YORK, Oct. 29, 2020 /PRNewswire/ -- The research antibodies and reagents market is projected to reach USD 14.1 billion by 2025 from USD 10.1 billion in 2020, at a CAGR of 6.7% during the forecast period. The research antibodies and reagents market has evolved owing to factors such as growth in proteomics and genomics research, rising demand for high-quality antibodies for research reproducibility, and increasing R&D activity and expenditure in the life sciences industry. Fueled by the growing demand for personalized medicine and structure-based drug design, the global research antibodies and reagents market is expected to witness significant growth in the coming years.

Read the full report: https://www.reportlinker.com/p05979661/?utm_source=PRN

Based on product, the reagents segment holds the highest market share during the forecast period.Based on product, the research antibodies and reagents market are segmented into reagent and antibodies.The reagent segment accounted for the larger market share in 2019.

The reagents market is experiencing notable growth due to the growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields.

Based on technology, the flow cytometry segment is expected to register the highest CAGR during the forecast period.Based technology, the research antibodies and reagents market is segmented into western blotting, flow cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies.The flow cytometry segment is expected to witness the highest growth during the forecast period.

This is mainly due to this technique is its ability to perform simultaneous multi-parameter analysis on single cells within a heterogeneous mixture.It offers high throughput and the automated quantification of cell features.

These factors, along with technological innovations in flow cytometry and growing cancer research, are driving the growth of this segment. By application , the proteomics holds the highest market share during the forecast period.

Based on application, the research antibodies and reagents market is segmented into proteomics, drug development and Genomics. Proteomics held the largest share of the global research antibodies and reagents market in 2019.The growth of the segment is due to as it efficiently maps drug-protein and protein-protein interactions. Moreover, proteomic technologies have minimized the cost, time, and resource requirements for chemical synthesis and biological testing of drugs. Proteomic technologies, such as electrophoresis, ELISA, microarrays, and MS-based proteomics, are highly efficient for analytical laboratory testing.

By enduser , the pharmaceutical & biotechnology holds the highest market share during the forecast period.The research antibodies and reagents market is segmented into the pharmaceutical & biotechnology companies, academic & research institutions and Contract Research Organizations.The pharmaceutical & biotechnology companies held the largest share of the global research antibodies and reagents end-user market in 2019.

The large share of this segment is attributed to the wide use of research antibodies in drug development for the identification and quantification of biomarkers and various analytical procedures. By Region, The Asia Pacific region is expected to register the highest CAGR during the forecast period.

The Asia Pacific research antibodies and reagents market is expected to grow at the highest CAGR from 2020 to 2025.The growth of this market is primarily due to growing proteomics and genomics research and increasing research funding, investments by pharmaceutical and biotechnology companies, and growing awareness of personalized therapeutics in the region. Also high-growth countries, such as China, India, Japan, South Korea, Taiwan, Australia, and Singapore are the major contributors to the Asia Pacific research antibodies and reagents market. This region is expected to grow at the highest pace during the forecast period primarily due to growing proteomics and genomics research and increasing research funding, increasing investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics.

Break of primary participants was as mentioned below: By Company Type Tier 135%, Tier 245% and Tier 320% By Designation C-level35%, Director-level25%, Others40% By Region North America45%, Europe30%, Asia Pacific20%, Latin America- 3%, Middle East and Africa2%

Key players in the research antibodies and reagents marketThe key players operating in the researsch antibodies and reagents systems include Thermo Fisher Scientific (US), Merck Group (Germany), Abcam plc (UK), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), Danaher Corporation (US), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), GenScript (China), and BioLegend (US).

Research Coverage:The report analyzes the research antibodies and reagent market and aims at estimating the market size and future growth potential of this market based on various segments such as product, distribution channel, and region.The report also includes a product portfolio matrix of various research antibodies and reagents products available in the market.

The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the ReportThe report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers: Market Penetration: Comprehensive information on product portfolios offered by the top players in the global research antibodies and reagent market. The report analyzes this market by product and distribution channel. Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global research antibodies and reagent market. Market Development: Comprehensive information on the lucrative emerging markets by product and distribution channel Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global research antibodies and reagent market. Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global research antibodies and reagent market.

Read the full report: https://www.reportlinker.com/p05979661/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: [emailprotected] US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Read this article:
The Asia Pacific research antibodies and reagents market is expected to grow at the highest CAGR from 2020 to 2025 - PRNewswire

NEW YORK--(BUSINESS WIRE)--Medidata, a Dassault Systmes company, the global leader in creating end-to-end solutions that support the entire clinical trial process, will convene stakeholders in drug and device development, clinical operations, data management, biostatistics and digital medicine innovation industries for NEXT Global on October 27-29, 2020.

With a focus on improving clinical trials through advanced technology and enhancing the patient experience, the three-day, all virtual event will bring together experts to discuss topics critical to pharmaceutical and biotechnology companies, medical device and diagnostics companies, and contract research organizations (CROs) running clinical trials during the COVID-19 pandemic.

The COVID-19 pandemic is reshaping the life sciences industry and is acting as a catalyst for dramatic change, said Tarek Sherif, co-founder and co-CEO of Medidata. Digital transformation of life sciences is happening at an accelerated pace, from research to clinical trials, manufacturing and through to commercialization. Nowhere is this more apparent than in clinical studies, where the use of advanced analytics is powering faster, safer and more effective treatments. Medidatas platform is at the forefront of enabling clinical development to improve the patient experience and patient outcomes.

To see and hear how Medidatas industry-leading Rave platform and its innovative patient-centric approach is at the core of digitally transforming clinical trials, attendees will participate in sessions with the following themes:

Presentations from Medidata experts, customers, partners and industry experts will focus on the next phase of digital transformation in clinical trials and drug development through:

The right unified technology can embrace the waves of change and increase precision in medical therapies and treatments, said Glen de Vries, co-CEO of Medidata. NEXT Global will showcase technology solutions that accelerate clinical development, powering smarter treatments and healthier people.

Medidata is a wholly owned subsidiary of Dassault Systmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization.

About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,600+ customers and partners access the world's most-used platform for clinical development, commercial, and real-world data. Medidata, a Dassault Systmes company (Euronext Paris: #13065, DSY.PA), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at http://www.medidata.com and follow us @Medidata, The Operating System for Life SciencesTM.

Medidata and Medidata Rave are registered trademarks of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systmes.

About Dassault Systmes

Dassault Systmes, the 3DEXPERIENCE Company, is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual experience twins of the real world with our 3DEXPERIENCE platform and applications, our customers push the boundaries of innovation, learning and production. Dassault Systmes brings value to more than 270,000 customers of all sizes, in all industries, in more than 140 countries. For more information, visit http://www.3ds.com.

3DEXPERIENCE, the Compass icon, the 3DS logo, CATIA, BIOVIA, GEOVIA, SOLIDWORKS, 3DVIA, ENOVIA, EXALEAD, NETVIBES, MEDIDATA, CENTRIC PLM, 3DEXCITE, SIMULIA, DELMIA, and IFWE are commercial trademarks or registered trademarks of Dassault Systmes, a French socit europenne (Versailles Commercial Register # B 322 306 440), or its subsidiaries in the United States and/or other countries.

Read more here:
Medidata NEXT Global 2020 to Focus on the Virtualization of Clinical Trials, the Power of Analytics and Improving the Patient Experience in the...

Oct. 26, 2020 16:00 UTC

OAKLAND, Calif.--(BUSINESS WIRE)-- In a step toward the full realization of genomic medicine, Fabric Genomics (Formerly Known As Omicia, Inc.), a leader in AI-based genomic analysis and interpretation, has announced a co-marketing agreement that will provide translational researchers around the world with integrated sample prep to reporting workflows. Combining Roches newly released KAPA HyperExome Probes (RUO) with the Fabric Enterprise bioinformatics and analysis platform will make genetic research faster, less costly and more accurate by providing an end-to-end solution from sample prep through analysis.

Fabric Genomics pioneered AI-driven genomic interpretation, and its Fabric Enterprise software platform for genomic data analysis and reporting is in use by clinical research laboratories, healthcare institutions and country sequencing programs around the world, including Rady Childrens Institute for Genomic Medicine, LabCorp and Genomics England. Last week Fabric Genomics released Fabric GEM, a novel algorithm that quickly identifies the likely genetic cause of rare diseases; the new technology is fully integrated within the Fabric Enterprise platform.

Roches exome sequencing workflow includes the KAPA HyperPrep and HyperPlus library preparation kits and exome probes, which allow users to quickly prepare samples for sequencing while delivering high on-target rates and 98% sensitivity for SNP detection.

In addition to improving turnaround times for genomic sequencing, the combination of these technologies will allow laboratories to increase automation and lower operational costs with improved scalability. Clinical research labs that are expanding assay menus will benefit from reduced costs of development and faster validation.

Clinical research labs have a need to take a collected sample from library prep quickly, all the way through to analysis, and our agreement with Roche demonstrates our commitment to supporting these critical workflows, said Martin Reese, PhD, co-founder and CEO of Fabric Genomics. Using our Fabric Enterprise analysis platform with Roche KAPA HyperExome Probes ensures high coverage of disease-causing genes, which is of the utmost importance in accelerating the identification of rare variants. Combining these technologies into a single workflow will lead to higher quality results and increased reliability of sequencing-based diagnostics in routine care. With widespread adoption of sequencing technology innovation, we can further our shared goal of improving personalized care.

KAPA products are for research use only (RUO). Not for use in diagnostic procedures.

About Fabric Genomics

Headquartered in Oakland, California, Fabric Genomics was founded by industry veterans and innovators with a deep understanding of bioinformatics, large-scale genomics and clinical diagnostics. Fabric Genomics is making genomics-driven precision medicine a reality. The company also provides clinical decision-support software that enables clinical labs, hospital systems and country sequencing programs to gain actionable genomic insights, resulting in faster and more accurate diagnoses and reduced turnaround time. Fabrics end-to-end genomic analysis platform incorporates proven AI algorithms, and has applications in both hereditary disease and oncology.

To learn more, visit https://fabricgenomics.com/roche/ and follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005324/en/

See original here:
Fabric Genomics to Co-market Comprehensive Sample-to-Genomic Analysis Sequencing Solutions for Hereditary Genetics - BioSpace

Mid-cap stocks are oftenunfairlyoverlooked. In a coronavirus-stricken economy where giant tech companies keep powering the market higher as small companies struggle to survive, mid-caps are an excellent compromise. They generally have lower valuations than the most beloved blue chips and stronger businesses than the small fries.

In fund tracker Morningstars Mid-Cap Blend category, the $552 million Madison Mid Cap fund (ticker: GTSGX) is one of the best. The no-load fund has beaten 95% of its category peers in the past three years and 85% of them in the past 15. Equally important, it is less volatile than its Russell Midcap benchmark, while matching the indexs 11.8% average annual return in the past 10 years. (Although officially this Y-share class of the fund has a $25,000 minimum investment, brokers such as Fidelity, Charles Schwab, TD Ameritrade, and E*Trade allow clients to get into the fund with an investment of $2,500 or less.)It has an expense ratio of 0.95%.

Manager Rich Eisinger, 55, has been at the helm since 1998, but he also relies on Haruki Toyama, co-manager since 2015, and Andy Romanowich, co-manager since 2019. Eisingers connection with Toyama, 49, goes way back. They first met at an investment club in the 1990s at Cornell Universitys business school, and both were Warren Buffett fans. We showed up at a room for new club members, and this fellow student got up, and started talking about options this and options that, and Rich and I kind of looked at each other and were like, Whats this guy talking about? We just want to buy great companies at a cheap price, Toyama recalls. They have been friends since then, swapping investment ideas, going on research trips together, and sharing investment philosophies.

Eisingers investment style, like Buffetts, has evolved from a more traditional value approachseeking cheap stocksto trying to invest in great businesses with strong durable cash flows. Over time, weve realized, especially in the mid-cap space, the value of paying up for a great business and watching that free cash flow compound over many years, Eisinger says. Madison Mid Cap tends to hold stocks for the long termthe funds turnover ratio is 25%, indicating a typical holding period of four years. Forty percent of our portfolio weve owned for over a decade, Toyama says.

The fund is also concentratedanother Buffett hallmarkhaving just 29 stocks as of Sept. 30. Concentration increases individual stock risk, as any blowups in a 5% position hurt returns more than a 1% one, for instance. But the funds volatility is low, despite its small number of stocks, reflecting the high quality of its holdings and the rarity of individual company blowups.

To make it into the portfolio, a company should have a strong business model with an economic moat that prevents competitors from reducing profits. It must also have a superior management team with preferably strong insider ownership, conservative accounting and earnings projections, and a history of wise capital-allocation decisions regarding share buybacks, acquisitions, and debt repayment. Finally, the valuation must be reasonable for a strong business.

Note: Holdings as of Sept. 30. Returns through Oct. 26; all returns are annualized.

Sources: Madison Funds; Morningstar

Health-care diagnostics company Laboratory Corp. of America Holdings (LH), commonly known as LabCorp, exemplifies the funds buy-and-hold strategy. Were in the 17th year now of ownership, Eisinger says. LabCorp and Quest Diagnostics (DGX) are the two largest clinical diagnostics labs in the country, controlling 25% of the independent lab business, he says. Eisinger sees a long runway for earnings growth between 10% to 11% a year because LabCorp is the low-cost provider of diagnostic tests relative to hospital labs. Theres more emphasis on [health-care] cost containment than theres ever been, so [LabCorp] is going to start gaining more market share in the next decade.

Moreover, in 2015 LabCorp acquired drug developer Covance, which specializes in personalized medicine, such as targeted gene therapies. Covance can utilize LabCorps huge database of patients to get candidates for their drug trials and their drug development, Eisinger says. That patient access should give Covance an advantage in the burgeoning personalized medicine business.

Another favorite, property and casualty insurer Arch Capital Group (ACGL), has a CEO, Marc Grandisson, who embodies the Buffett-like qualities that the fund managers seek. In fact, in the 1990s, Grandisson actually worked at Berkshire Hathaway (as did his predecessor, Constantine Iordanou, who is now retired). Under Grandissons aegis, Arch has been an excellent capital allocator and one of the few insurers to make a profit from its policy underwriting, Toyama says. Historically, the industry has lost money underwriting, and made it up in investments, he says, referring to how insurers typically use money from policy premiums to buy bonds and stocks.

Archs insurance underwriting has been successful because Grandisson is willing to walk away from business when a policy type becomes less profitable or commodity-like due to competition, Toyama says. It has decreased its major casualty insurance business over the years as it got more price competitive, he explained. The companys stock has taken a shellacking in 2020, down 29%, because of claims related to Covid-19. But it is precisely after such calamities that insurance premiums go up and profitability increases, Toyama says. The fund is staying put.

Typical of a high-quality mid-cap portfolio, many of the funds holdings are industry leaders but not household names. So 16% of its portfolio is in technology, but not in the Amazon.coms (AMZN) of the world. Instead, the fund invests in companies like tech research publisher and consultant Gartner (IT).

Newsletter Sign-up

Every weekday evening we highlight the consequential market news of the day and explain what's likely to matter tomorrow.

Gartner has a very attractive business model in that its core product is a written research service that is sold on a subscription basis, Romanowich says. So, it has very visible, highly recurring revenue. The company has a major advantage as the leading research intermediary between tech buyers and sellers, he says. Gartner knows what end users want, and what corporations tech road maps look like. They also know what tech vendors are thinking and what their technology road maps look like.

That informational advantage provides an economic moat any Warren Buffett fan would admire.

Write to editors@barrons.com

Read more from the original source:
This Mid-Cap Stock Fund Wins With Warren Buffetts Strategy - Barron's

Regenerative medicine is a part of translational research in the fields of molecular biology and tissue engineering. This type of medicine involves replacing and regenerating human cells, organs, and tissues with the help of specific processes. Doing this may involve a partial or complete reengineering of human cells so that they start to function normally.

Get Exclusive PDF Sample Copy Of This Report:https://www.tmrresearch.com/sample/sample?flag=B&rep_id=1889

Regenerative medicine also involves the attempts to grow tissues and organs in a laboratory environment, wherein they can be put in a body that cannot heal a particular part. Such implants are mainly preferred to be derived from the patients own tissues and cells, particularly stem cells. Looking at the promising nature of stem cells to heal and regenerative various parts of the body, this field is certainly expected to see a bright future. Doing this can help avoid opting for organ donation, thus saving costs. Some healthcare centers might showcase a shortage of organ donations, and this is where tissues regenerated using patients own cells are highly helpful.

There are several source materials from which regeneration can be facilitated. Extracellular matrix materials are commonly used source substances all over the globe. They are mainly used for reconstructive surgery, chronic wound healing, and orthopedic surgeries. In recent times, these materials have also been used in heart surgeries, specifically aimed at repairing damaged portions.

Cells derived from the umbilical cord also have the potential to be used as source material for bringing about regeneration in a patient. A vast research has also been conducted in this context. Treatment of diabetes, organ failure, and other chronic diseases is highly possible by using cord blood cells. Apart from these cells, Whartons jelly and cord lining have also been shortlisted as possible sources for mesenchymal stem cells. Extensive research has conducted to study how these cells can be used to treat lung diseases, lung injury, leukemia, liver diseases, diabetes, and immunity-based disorders, among others.

Buy This Report @https://www.tmrresearch.com/checkout?rep_id=1889<ype=S

Global Regenerative Medicine Market: Overview

The global market for regenerative medicine market is expected to grow at a significant pace throughout the forecast period. The rising preference of patients for personalized medicines and the advancements in technology are estimated to accelerate the growth of the global regenerative medicine market in the next few years. As a result, this market is likely to witness a healthy growth and attract a large number of players in the next few years. The development of novel regenerative medicine is estimated to benefit the key players and supplement the markets growth in the near future.

Global Regenerative Medicine Market: Key Trends

The rising prevalence of chronic diseases and the rising focus on cell therapy products are the key factors that are estimated to fuel the growth of the global regenerative medicine market in the next few years. In addition, the increasing funding by government bodies and development of new and innovative products are anticipated to supplement the growth of the overall market in the next few years.

On the flip side, the ethical challenges in the stem cell research are likely to restrict the growth of the global regenerative medicine market throughout the forecast period. In addition, the stringent regulatory rules and regulations are predicted to impact the approvals of new products, thus hampering the growth of the overall market in the near future.

Global Regenerative Medicine Market: Market Potential

The growing demand for organ transplantation across the globe is anticipated to boost the demand for regenerative medicines in the next few years. In addition, the rapid growth in the geriatric population and the significant rise in the global healthcare expenditure is predicted to encourage the growth of the market. The presence of a strong pipeline is likely to contribute towards the markets growth in the near future.

Global Regenerative Medicine Market: Regional Outlook

In the past few years, North America led the global regenerative medicine market and is likely to remain in the topmost position throughout the forecast period. This region is expected to account for a massive share of the global market, owing to the rising prevalence of cancer, cardiac diseases, and autoimmunity. In addition, the rising demand for regenerative medicines from the U.S. and the rising government funding are some of the other key aspects that are likely to fuel the growth of the North America market in the near future.

Furthermore, Asia Pacific is expected to register a substantial growth rate in the next few years. The high growth of this region can be attributed to the availability of funding for research and the development of research centers. In addition, the increasing contribution from India, China, and Japan is likely to supplement the growth of the market in the near future.

Global Regenerative Medicine Market: Competitive Analysis

The global market for regenerative medicines is extremely fragmented and competitive in nature, thanks to the presence of a large number of players operating in it. In order to gain a competitive edge in the global market, the key players in the market are focusing on technological developments and research and development activities. In addition, the rising number of mergers and acquisitions and collaborations is likely to benefit the prominent players in the market and encourage the overall growth in the next few years.

Some of the key players operating in the regenerative medicine market across the globe are Vericel Corporation, Japan Tissue Engineering Co., Ltd., Stryker Corporation, Acelity L.P. Inc. (KCI Licensing), Organogenesis Inc., Medtronic PLC, Cook Biotech Incorporated, Osiris Therapeutics, Inc., Integra Lifesciences Corporation, and Nuvasive, Inc. A large number of players are anticipated to enter the global market throughout the forecast period.

To know more about the table of contents, you can click @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1889

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to busi-ness entities keen on succeeding in todays supercharged economic climate. Armed with an experi-enced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Originally posted here:
Regenerative Medicine Market Poised to Garner Maximum Revenues During 2025 - The Think Curiouser

AllTheResearchs latest research report provides an overview of theRegenerative Medicine market with segmentation, regional analysis and discussion of important industry trends, market share estimates and profiles of the leading key players. The identified trends that are very helpful for business decisions. The Regenerative Medicine Industry report is a valuable source of guidance for the new and prominent growths of the enterprise, the competitive evaluation, and nearby assured analysis for the reviewing size.

The global Regenerative Medicine market was valued at US$ 13.56 Mn in 2018 and is expected to reach US$ 55.67 Mn in 2026, growing at a CAGR of 23% during the forecast period.

Request for Sample with Complete TOC and Figures & Graphs @ https://www.alltheresearch.com/sample-request/232

Company Profiles mapped in Regenerative Medicine market with Competitive Intelligence:

Market Segmentation by Type, Application and Region

Based on Product Type:

Based on Application:

The Global Regenerative Medicine market analyses and researches the Regenerative Medicine development status and forecast in the United States, Europe, China, Japan, Southeast Asia, India and Central and South America. The Global Regenerative Medicine Market focuses on global major leading industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue, and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out.

The Regenerative Medicine industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions offered. The Regenerative Medicine Market report provides key statistics on the market status of the Regenerative Medicine manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Any questions, Lets discuss with the analyst @ https://www.alltheresearch.com/speak-to-analyst/232

How Report will help you to make decisions for business:

Browse report along with TOC, Table & figures, research methodology and many more @ https://www.alltheresearch.com/report/232/Regenerative Medicine

About AllTheResearch:

AllTheResearch was formed with the aim of making market research a significant tool for managing breakthroughs in the industry. As a leading market research provider, the firm empowers its global clients with business-critical research solutions. The outcome of our study of numerous companies that rely on market research and consulting data for their decision-making made us realise, that its not just sheer data-points, but the right analysis that creates a difference.While some clients were unhappy with the inconsistencies and inaccuracies of data, others expressed concerns over the experience in dealing with the research-firm. Also same-data-for-all-business roles was making research redundant. We identified these gaps and built AllTheResearch to raise the standards of research support.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:

Contact Name: Rohan S.

Email:[emailprotected]

Phone: +1 (407) 768-2028

See more here:
Regenerative Medicine Market By Key Players, Product And Production Information Analysis And Forecast To 2026 - PRnews Leader

Over the last three months I served on the Patient and Medical Advisory Committee for Prop. 14, which will renew support for the California Institute for Regenerative Medicine (CIRM).

It has been an honor and privilege to advocate for CIRM, because the research, education, and clinical trials it supports will save lives and reduce suffering. Were a diverse group, including patients, advocates, scientists, and students - brought together by the power of a state agency that has enabled a cure for children born without an immune system - so called bubble babies, and treatments for blindness and cancer.

In addition to a possible cure for diabetes, more than 90 other regenerative treatments and cures are in clinical trials. It is impossible to argue with these accomplishments.

Given that, some will argue against the economics of supporting CIRM through Prop. 14, which will involve the sale of $5.5 billion in bonds over the next 20 years. Contrast that to the $300 billion per year spent in California on healthcare.

Even if the only thing that comes from CIRM support is a cure for diabetes, it will pay for itself many times over, given that diabetes cost California $30 billion per year. But CIRM wont just enable a cure for diabetes - treatments and cures are being developed for dozens of other chronic diseases and conditions.

Can we afford Prop. 14 now, in the middle of the COVID-19 recession? We can. Bond repayments wont start for five years. After that, state revenue stimulated by CIRM will cover bond payments until 2030. At the same time, renewing support of CIRM will create 100,000 jobs. That is exactly the sort of stimulus we need right now.

View post:
Letters to the Editor: We can afford Prop. 14; Voting for Jordan Cunningham; Poll workers should be tested before, after election - Santa Maria Times

Over the last three months I served on the Patient and Medical Advisory Committee for Prop. 14, which will renew support for the California Institute for Regenerative Medicine (CIRM).

It has been an honor and privilege to advocate for CIRM, because the research, education, and clinical trials it supports will save lives and reduce suffering. Were a diverse group, including patients, advocates, scientists, and students - brought together by the power of a state agency that has enabled a cure for children born without an immune system - so called bubble babies, and treatments for blindness and cancer.

In addition to a possible cure for diabetes, more than 90 other regenerative treatments and cures are in clinical trials. It is impossible to argue with these accomplishments.

Given that, some will argue against the economics of supporting CIRM through Prop. 14, which will involve the sale of $5.5 billion in bonds over the next 20 years. Contrast that to the $300 billion per year spent in California on healthcare.

Even if the only thing that comes from CIRM support is a cure for diabetes, it will pay for itself many times over, given that diabetes cost California $30 billion per year. But CIRM wont just enable a cure for diabetes - treatments and cures are being developed for dozens of other chronic diseases and conditions.

Can we afford Prop. 14 now, in the middle of the COVID-19 recession? We can. Bond repayments wont start for five years. After that, state revenue stimulated by CIRM will cover bond payments until 2030. At the same time, renewing support of CIRM will create 100,000 jobs. That is exactly the sort of stimulus we need right now.

Originally posted here:
Letters to the Editor: We can afford Prop. 14 - Hanford Sentinel

The report on Global Orthopedic Regenerative Medicine Market is a dependable point of reference heralding high accuracy business decisions on the basis of thorough research and observation by seasoned research professionals at CMI Research. The report on global Orthopedic Regenerative Medicine market evidently highlights the causal factors such as demand analysis, trend examination, and technological milestones besides manufacturing activities that have been systematically touched upon to instigate systematic growth projection.

This CMI Research report on global Orthopedic Regenerative Medicine market systematically studies and follows noteworthy progresses across growth trends, novel opportunities as well as drivers and restraints that impact growth prognosis.

Free Sample Report + All Related Graphs & Charts @:https://www.coherentmarketinsights.com/insight/request-sample/3566

Which market players and aspiring new entrants may witness seamless entry?

Curasan, Inc., Carmell Therapeutics Corporation, Anika Therapeutics, Inc., Conatus Pharmaceuticals Inc., Histogen Inc., Royal Biologics, Ortho Regenerative Technologies, Inc., Swiss Biomed Orthopaedics AG, Osiris Therapeutics, Inc., and Octane Medical Inc.

Predicting Scope: Global Orthopedic Regenerative Medicine Market, 2020-2027

Elaborate research proposes global Orthopedic Regenerative Medicine market is likely to experience an impressive growth through the forecast span, 2020-2027, ticking a robust CAGR of xx% USD. The Orthopedic Regenerative Medicine market is anticipated to demonstrate a whopping growth with impressive CAGR valuation. The Orthopedic Regenerative Medicine market is also likely to maintain the growth spurt showing signs of steady recovery.

For appropriate analysis of all the market relevant information as well emerging trends and historical developments in the Orthopedic Regenerative Medicine market, CMI Research has referred to various primary and secondary research practices and contributing factors.

Regional Overview: Global Orthopedic Regenerative Medicine Market

The report specifically sheds light upon note-worthy business discretion, popular trends investment probabilities aligning with budding opportunities as well as breakthrough developments in policies and monetary inclination echoing investor preferences in Orthopedic Regenerative Medicine space.

Competitive Landscape: Global Orthopedic Regenerative Medicine Market

Further in the report, readers are presented with minute details pertaining to significant company profiles, product development, on pricing, production and vital information on raw material and equipment developments also form crucial report contents in this CMI Research report.

Have Any Query? Ask Our Expert @: https://www.coherentmarketinsights.com/insight/request-customization/3566

Segmentation Based on Orthopedic Regenerative Medicine Market Types:

By Procedure Cell TherapyTissue EngineeringBy Cell TypeInduced Pluripotent Stem Cells (iPSCs)Adult Stem CellsTissue Specific Progenitor Stem Cells (TSPSCs),Mesenchymal Stem Cells (MSCs)Umbilical Cord Stem Cells (UCSCs)Bone Marrow Stem Cells (BMSCs)By SourceBone MarrowUmbilical Cord BloodAdipose TissueAllograftsAmniotic FluidBy ApplicationsTendons RepairCartilage RepairBone RepairLigament RepairSpine RepairOthers

Global Orthopedic Regenerative Medicine Market Size & Share, By Regions and Countries/Sub-regions:

Asia Pacific: China, Japan, India, and Rest of Asia Pacific

Europe: Germany, the UK, France, and Rest of Europe

North America: the US, Mexico, and Canada

Latin America: Brazil and Rest of Latin America

Middle East & Africa: GCC Countries and Rest of Middle East & Africa

The regional analysis segment is a highly comprehensive part of the report on the global Orthopedic Regenerative Medicine market. This section offers information on the sales growth in these regions on a country-level Orthopedic Regenerative Medicine market.

The historical and forecast information provided in the report span between2020 and 2027. The report provides detailed volume analysis and region-wise market size analysis of the market.

Report Investment, a Priority: Explains CMI Research

This report also helps market participants to organize R&D activities aligning with exact market requirements

The report resonates critical findings on decisive factors such as downstream needs and requirement specifications as well as upstream product and service development

The report aids in reader comprehension of the market based on dual parameters of value and volume.

This CMI Research initiated research output on Orthopedic Regenerative Medicine market is a ready-to-refer handbook of noteworthy cues for easy adoption by market players and stakeholders

CMI Research skillfully underpins a vivid segment analysis of the global Orthopedic Regenerative Medicine market, rendering appropriate inputs about the revenue generation capabilities of each segment.

Buy this research report @: https://www.coherentmarketinsights.com/insight/buy-now/3566

Thanks for reading our report. If you have any further questions, please contact us. Our team will provide you with the report tailored to your needs.

About Us:

Coherent Market Insightsis a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contacts Us: +1-206-701-6702Email:[emailprotected]Web:https://www.coherentmarketinsights.com/

See more here:
Covid-19 Impact On Orthopedic Regenerative Medicine Market 2020 Future Development, Manufacturers, Trends, Share, Size And Forecast to 2027 |...

After kicking off the Prescription Drug User Fee Act (PDUFA) reauthorization process in July, the US Food and Drug Administration (FDA) has released the first set of meeting summaries in its ongoing negotiations with industry that will shape its prescription drug review program from FY2023-2027.The meeting summaries, while brief, provide insights into what FDA and industry hope to get out of the multi-billion-dollar agreement, with representatives from government and industry alike agreeing that the exploding field of advanced biologic therapies must be a priority. In some other areas, though, the wish lists diverged. (RELATED: PDUFA VII: FDA, industry preview their reauthorization wish lists, Regulatory Focus 23 July 2020).Steering committeeThe PDUFA reauthorization steering committee met three times in September to hash out the ground rules for the negotiations and review the major topics and proposals both sides will work through via designated working groups.FDA and industry both noted the impact of the COVID-19 pandemic on the agency and the reauthorization process at the first meeting on 15 September.Despite historic workload and operating challenges in the time period, the steps taken in PDUFA VI to protect the program from financial uncertainty have proven critical and important to maintaining FDAs operations, FDA said.During the meeting, FDA pitched six areas it wants to focus on for PDUFA VII: digital health and informatics, postmarket, CBER-specific enhancements, pre-market, regulatory decision tools and finance.Industry, on the other hand, expressed interest in build[ing] upon past user fee agreements and to ensure FDA and industry can mutually keep pace with scientific development. Topics presented by industry include: strengthening scientific dialogue, enhancing patient-centric drug review, supporting the next wave of advanced biologic therapies, modernizing regulatory evidence generation, advancing digital and IT technologies, enhancing innovation in quality and manufacturing, and optimizing FDA infrastructure, staffing, and resources.Industry also said it was keen on adopting some of the lessons from the COVID-19 pandemic and translating them into improved processes going forward.During the next steering committee meeting on 22 September, FDA and industry reviewed the overall timeline for reauthorization and the two sides sought clarification on each others proposed topics. The following week the committee met again and reviewed the timeline for communicating with Congress, agreed to topic assignments and looked at some of the overlap between the agencys COVID-19 response and PDUFA interests.CBER subgroupIncreased support for FDAs Center for Biologics Evaluation and Research (CBER) is set to be a focus for both FDA and industry in the negotiations.FDA told industry at the first CBER breakout meeting that it would like to see enhanced resources for its cell and gene therapy program, which has been overwhelmed by an influx of applications and meeting requests in recent years.FDA noted that its new regenerative medicine advanced therapy (RMAT) designation program has seen exponential growth and is now outpacing breakthrough therapy designations in the Office of Tissues and Advanced Therapies (OTAT), despite not receiving any dedicated resources for the fledgling program.With more resources, FDA told industry that it could spend more time on cell and gene therapy submissions, provide more opportunities for engagement and develop policy and guidance for sponsors. FDA also said it will seek dedicated resources for the RMAT program under PDUFA VII.Industry suggested three CBER-related commitments it would like to work into the reauthorization agreement, including workshops and guidance on the use of sponsor-specific prior knowledge in gene therapy submissions, evidentiary standards for RMAT designation and gene therapy manufacturing issues.Industry would like a public workshop to focus on key learnings from the RMAT program resulting in an update to the RMAT guidance, including potential uses of Real World Evidence (RWE) for regulatory decision making, FDA writes, noting that meaningful guidance on the matter may be difficult to develop due to the limited number of approved cell and gene therapy products and the fact that there have not been any products approved to date with RMAT designation.For gene therapy manufacturing, industry specifically said it would like to explore whether submitting portions of a chemistry, manufacturing and controls (CMC) module could facilitate biologics license approval (BLA) review. FDA said it has concerns that a partial submission could actually slow approval down if development is ongoing but agreed to carry the discussion forward.Regulatory decision toolsOn 29 September, the regulatory decision tools subgroup met for the first time, with FDA and industry reviewing potential areas of enhancement and agreeing to a schedule for the next several meetings.FDA raised four topics it would like to tackle in PDUFA VII, including model-informed drug development (MIDD), complex innovative trial designs (CID), patient-focused drug development (PFDD), and advancing translational models and tools for drug development (ATMT).For MIDD, FDA said its goal is to build on the lessons learned during PDUFA VI and to ensure the programs sustainability. Doing so would require public engagement and the development of comprehensive end-to-end guidance, which FDA said would necessitate increased staffing.Digital health and informaticsFDA and industry began discussions aimed at enhancing the use of digital health and informatics technologies under PDUFA VII on 30 September.FDA pitched three topics for discussion at the meeting, including a proposal for an integrated cloud-based technology environment, a framework for leveraging digital health technology-generated data in submissions, and CBER IT modernization.PremarketFDA and industry addressed several premarket issues in the first meeting of the premarket subgroup, including user related risk analysis (URRA) and human factor (HF) protocol review and developing efficacy endpoints for rare diseases.FDA proposed increasing the user fee timeline for reviewing HF protocols and said the current goals will be unsustainable in the future due to increasing volume and complexity of HF submissions. The two sides discussed the creation of a new user fee goal and timeline for review of URRA.FinanceAt the first of two finance subgroup meetings, FDA presented a host of goals for PDUFA VII: To enhance the operational capabilities, efficacy, and agility of the PDUFA program. FDA proposed continuing to advance resource capacity planning, updating the inflation adjustment to accurately account for program costs, enhancing flexibility in the operating reserve, eliminating a problematic limitation on allowable expenditures, streamlining annual reporting requirements, and implementing technical fixes.Industry representatives, however, stressed that their goal is to build on the enhancements made in PDUFA VI and to improve on user fee resource management, hiring and retention of review staff and performance reporting.During the second finance meeting, FDA and industry looked at a proposal to clarify the maximum and minimum amount of operating reserves to be maintained each year and a proposal to further implement the resource capacity planning (RCP) capability instituted in PDUFA VI.Stakeholder meetingFDA also released a meeting summary from the first round of stakeholder discussions. More than 60 stakeholder organizations, including patient groups, consumer representatives, public health advocates and medical associations, registered to attend the meeting, though a third of those registered did not attend.Some of the themes frequently cited by stakeholders included enhancing the incorporation of patient voice in drug development and regulatory decision making, modernizing FDAs infrastructure, ensuring FDA has adequate resources to recruit and retain qualified staff including in the areas of cell and gene therapy, increasing the strength and reach of patient and rare disease programs including improving diversity in clinical trials and patient engagement, enhancing FDAs use of regulatory science (e.g. COAs, MIDD, RWE), and improving the integration of and guidance for the use of real-world evidence (RWE), FDA reported. Stakeholders also raised decentralized trials and lessons learned during the COVID-19 pandemic as topics for future discussions.FDA tasked stakeholders with identifying their top issues for further discussion and said it would survey them to rank the topics on the agreed to shortlist.FDA

See original here:
PDUFA VII: FDA and industry set priorities in first round of negotiations - Regulatory Focus

At the very heart of our Biblical tradition is this commandment from the Book of Leviticus: You shall not stand idly by the blood of your fellow. (Leviticus 19:16)

If we see our sisters or brothers in danger, our job is simple: Provide that help, come to their aid, do what is in our power to protect them and save them.

In the midst of a global pandemic, we feel the call to protect and promote the health and well-being of others even more urgently. Right now, we hear the call to uphold the ultimate Jewish value of pikuach nefesh (saving a life).

Sometimes, we live out that value in an immediate way. We donate blood today, which can save lives in real time. We provide support for basic needs to ensure that people in our community have enough to eat right now. But if we truly wish to move the needle in the work of pikuach nefesh, we must also provide resources to fund research over many years, even decades, that will, ultimately, yield dramatic results.

To truly make a difference, to be Gods partners in bringing healing to the world, we must not stand idly by in both immediate and long-term ways.

California voters have an opportunity to do just this by voting yes on Proposition 14, which will advance the California Institute of Regenerative Medicines stem cell research to help those who are affected by ailments including heart disease, diabetes, Alzheimers, Parkinsons disease, sickle cell disease, spinal cord injuries, Covid-19, and so many other chronic illnesses and injuries.

Funding for this important and vital medical research helps save lives, and it will provide immediate economic stimulus, as well. Even as it funds long-term strategies to alleviate human suffering, Prop. 14 will create jobs during this challenging time. Recent studiessuggest that Prop. 14 would generate approximately $20 billion in increased economic activity in California, yielding more than 100,000 new jobs at every level. This far surpasses Prop. 14s estimated cost of $5.5 billion in bonds.

Critics of the proposition question the need for such funding on a state level today. They argue that Proposition 71, the initiative that originally created the California Institute of Regenerative Medicine, was passed in 2004 only because President George W. Bush had banned federal funding for stem cell research. Now that federal funding for stem cell research is allowed, the critics charge, its no longer Californias responsibility to fund such research; private and federal funding should be used to continue this important work.

However, relying on federal and private funds is too risky. Many in our country wish to stifle and limit stem cell research on religious grounds. Far more importantly, Jewish law on this matter is unequivocal: stem cell research is not just permitted, but, arguably, required as a matter of pikuach nefesh. Numerous halachic authorities have made this clear. It should, therefore, come as no surprise that some of the most exciting work in stem cell research is currently being done in Israel.

Medical experts agree that stem cell research and therapies will save lives and alleviate human suffering. In fact, it already has. One example is the stem cell work Dr. Donald Kohn at UCLA conducted to cure ADA-SCID bubble baby disease.

This work is too important for us to leave it to chance or to allow it to be cut off or limited.

We see Prop. 14s opportunity to provide such resources for life-saving research as a blessing, the fulfillment of core Jewish values.

Just one chapter before the commandment to not stand idly by, our Torah reminds us that the purpose of mitzvot, the very goal of Judaism, is to enhance life. We are commanded: in the pursuit of My laws and statutes you shall live. (Leviticus 18:5) The Rabbis of the Talmud interpret this verse to mean that the ultimate value, above all else, is life itself.

To be sure, it will take many years to realize the promise of current research. But like the well-known story of Honi, who came upon an old man planting a tree that would not bear fruit for another 70 years, we recognize that our efforts are not for ourselves alone. Just as our ancestors sacrificed so that our lives would be better, we commit ourselves to doing the same for our descendants.

The voices of our sisters and brothers cry out to us: friends and family members with diabetes; co-workers fighting against cancer; loved ones slipping away due to the cruel ravages of Alzheimers.

They call out to us in their pain. They are searching for hope.

We cannot stand idly by. We must generously sacrifice so that they and subsequent generations might live and be well.

There are quite literally lives to be saved. Join us by voting yes on Prop, 14 on Nov. 3.

Read more from the original source:
We can't stand idly by: Vote 'yes' on Prop. 14 for stem cell research - The Jewish News of Northern California

Global Market Vision has published a newly innovative statistical data, titled as Regenerative Medicine Market. It is a valuable source of statistical data for Regenerative Medicine market and includes accurate information, which uses primary and secondary research techniques. The research analyst provides comprehensive data, which enhances the growth of the industries. This report focuses on the basic requirement strategies of the businesses, which helps to enlarge the productivity. Additionally, it offers different market segments, such as application, types, size, end users, cost etc.

Get Sample Copy (Including FULL TOC, Graphs and Tables) of this report @: https://www.globalmarketvision.com/sample_request/10671

It includes the research studies about the current trends in different sectors on the basis of their scope. The analyst of this report focuses on the static and dynamic pillars of the industries, for basic understanding of the strategies. In addition to this, it identifies the drivers and opportunities for the development of the businesses. Additionally, it focuses on restraints to analyze the issues from the existing business strategies. It focuses on the various aspects, such as application areas, platforms, and leading players operating across the globe.

Major Companies Profiled in this Report Includes: DePuy Synthes, Medtronic, ZimmerBiomet, Stryker, Acelity, MiMedx Group, Organogenesis, UniQure, Cellular Dynamics International, Osiris Therapeutics, Vcanbio, Gamida Cell, Golden Meditech, Cytori, Celgene, Vericel Corporation, Guanhao Biotech, Mesoblast, Stemcell Technologies, Bellicum Pharmaceuticals.

This statistical report is the comprehensive analysis of different barriers of Regenerative Medicine market. The detailed description of the historical data, current scenario and future predictions have been provided in the report. It gives accurate data of leading companies, which promotes the insights, to make great decisions in the businesses. In this report, you will also find additional data about the economics of the Regenerative Medicine market.

Global Regenerative Medicine Market Segmentation:

By Type/Product, Regenerative Medicine market has been segmented into: Cell Therapy, Tissue Engineering, Biomaterial, Other

By Application/End User, Regenerative Medicine has been segmented into: Dermatology, Cardiovascular, CNS, Orthopedic, Others

Regions Covered in the Global Regenerative Medicine Market: The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The global regions such as, North America, Latin America, Europe, Japan, and India are considered on the basis of the manufacturing, productivity, size, and revenue. This report is summarized with the competitive landscape along with the recent developments in Regenerative Medicine Market sectors for growth of the businesses.

Hurry Up! Get Up to 20% Discount on this Report@: https://www.globalmarketvision.com/check-discount/10671

The reports conclusion leads into the overall scope of the global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the global Regenerative Medicine market in the near future. The report will assist understand the requirements of customers, discover problem areas and possibility to get higher, and help in the basic leadership manner of any organization. It can guarantee the success of your promoting attempt, enables to reveal the clients competition empowering them to be one level ahead and restriction losses.

Global market research objectives:

Major questions addressed through this global research report:

Table of Content (TOC):

Chapter 1 Introduction and Overview

Chapter 2 Industry Cost Structure and Economic Impact

Chapter 3 Rising Trends and New Technologies with Major key players

Chapter 4 Global Regenerative Medicine Market Analysis, Trends, Growth Factor

Chapter 5 Regenerative Medicine Market Application and Business with Potential Analysis

Chapter 6 Global Regenerative Medicine Market Segment, Type, Application

Chapter 7 Global Regenerative Medicine Market Analysis (by Application, Type, End User)

Chapter 8 Major Key Vendors Analysis of Regenerative Medicine Market

Chapter 9 Development Trend of Analysis

Chapter 10 Conclusion

Place a Direct Order Of this Report: https://www.globalmarketvision.com/checkout/?currency=USD&type=single_user_license&report_id=10671

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

Any special requirements about this report, please let us know and we can provide custom report.

We are always happy to assist you on your queries: sales@globalmarketvision.com

Global Market Vision: http://www.globalmarketvision.com/

Continued here:
Regenerative Medicine Market Witnessing Significant Demand in the Global Market During 2020 2027 - Bipartisan Millennial

Colorado State University is no stranger to innovation, and in the past fiscal year, faculty, students, and staff received a record 69 new international and U.S. patents. These came from a similarly record-breaking 177 patent applications.

This feat put CSU, for the first time ever, on the National Academy of Inventors top 100 list of international universities for U.S. patents.

University patents ignite a culture of growth and innovation which in turn stimulates the economy, Jessica Landacre, executive director at the Intellectual Property Owners Association, which co-authored the NAIs report, said in a statement. Added NAIs President Paul Sanberg: The institutions included in this years report are leading innovation worldwide through their encouragement of academic discovery and invention.

The new patents were issued to researchers and inventors in the College of Agricultural Sciences; College of Business; Walter Scott, Jr. College of Engineering; College of Liberal Arts; College of Natural Sciences; College of Veterinary Medicine and Biomedical Sciences, and Facilities Management.

These patents have come through the Universitys technology transfer office, CSU Ventures. Technology transfer provides an avenue that helps to highlight important translational research at CSU and how it positively impacts peoples lives, locally and globally, said Sarah Hibbs-Shipp, director of outreach and communications for CSU Ventures. It also supports the land-grant mission of CSU.

In 2020, CSU Ventures selected Dr. Chris Orton, professor in the Department of Clinical Sciences, as the recipient of the Innovative Excellence Award. A leading authority in veterinary cardiovascular surgery, Orton is known for launching the first veterinary open-heart surgery program in the world.

One of Ortons patented technologies is licensed to Abbott Laboratories and contributed to the design of the companys Tendyne Transcatheter Mitral Valve Implantation system for human use. The system is approved for use in Europe, and is currently in review with the U.S. Food and Drug Administration. This life-changing therapy offers patients with significant mitral regurgitation a minimally invasive alternative to open-heart valve replacement surgery.

In addition to obtaining patents, faculty are also launching new startup companies with their innovations. Five were founded this past year with CSU intellectual property, with the assistance of CSU Ventures.

Startup companies are often the best path forward to bringing new technology to the marketplace, said Todd Headley, vice president of CSU Ventures. They also create jobs and have a positive impact on economic development.

Of the five startups, four of them were founded by CSU faculty and staff.

Of note, a COVID-related device technology developed by CSU researchers Brian Geiss of the Department of Microbiology, Immunology and Pathology; Chuck Henry of the Department of Chemistry; and David Dandy, of the Department of Chemical and Biological Engineering, was licensed to Quara Devices Ic. for further development. Ken Reardon of the Department of Chemical and Biological Engineering is the chief science officer of Quara Devices and helped initiate the licensing deal. The hope is that this small, inexpensive virus-detection technology will serve as the basis of a new product that could compete with standard diagnostic testing for the coronavirus that causes COVID-19.

In all, CSU investigators are currently working on more than 44 COVID-related projects.

These are wonderful demonstrations of how members of the CSU community were able to pivot their research and focus to solve real world, active problems, fully embodying the land-grant mission, Hibbs-Shipp said.

Link:
CSU innovators break record with 69 new patents in the past year - Source

New York, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Europe Cartilage Degeneration Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Procedure Type ; Application ; and End User and Country Regional Analysis and Market Forecasts by Procedure Type, Application and End User" - https://www.reportlinker.com/p05978846/?utm_source=GNW However, high cost of cartilage therapies and lack of reimbursement scenario are the factors restraining the growth of the market in this region.

Nevertheless, the growing number of product approvals and rising emphasis on regenerative medicines are likely to fuel the growth of the Europe cartilage degeneration market during the forecast period.Degeneration of cartilage leads to pain and chronic inflammation in joints of a human body.Furthermore, damaged cartilage can potentially influence the quality of a patients life.

Continuous research and developments are innovating new techniques and methodologies to deal with damaged cartilages. A few of these techniques comprise joint replacement, cell therapies, and chondroplasty.

Companies in the cartilage degeneration market are undertaking various R&D activities to introduce more innovative products. For instance, in September 2013, OligoMedic, Inc., a global designer, manufacturer, and distributor of osteoarthritis products, launched its CE mark injectable implant JointRep for the treatment of cartilage articular joint defect. Also, the new cartilage therapies are enabling the adoption of advanced cell technologies, which are, in turn, strengthening the procedural outcomes. Furthermore, in May 2017, Co.DON AG got European Medicines Agency (EMA) approval for its Spherox, a knee cartilage repair product for the treatment of symptomatic articular cartilage defects in femoral condyle and patella

The players operating in the cartilage degeneration market are focusing on establishing collaborations and partnerships for the development of advanced products with increasing procedural efficiency. For instance, in October 2018, Gelmetix, a UK-based player, and Stemmatters, a Portuguese regenerative medicine company, entered into a strategic partnership for the innovation and development of an advanced knee cartilage repair device. hus, the increasing number of product approvals, developments, advanced technologies, and strategic activities are projected to offer lucrative opportunities for the growth of the market.

The European economy is severely affected due to the exponential rise in the number of COVID-19 patients in this region.The Medical Device Regulation (MDR) requires manufacturers to conduct Post Market Clinical Follow-Up (PMCF) studies to demonstrate the continued safety and performance of their devices.

This is expected to impact the product launch and ongoing clinical trials of medical devices, thereby hampering the sales and market growth. Also, disrupted supply chains, extended lockdowns, and canceling of other medical procedures have adversely affected the growth of the cartilage degeneration market in Europe.The knee segment accounted for the largest share of the market in 2019.The growth of this segment is attributed to the increasing prevalence of knee injuries.

For instance, according to a study publishedbased on NCBI dataon an online newspaper, one in four adults suffer from chronic knee pain in this region. Moreover, the prevalence of knee pain has witnessed a massive growth of around 40.0% during the past 4 decades. Furthermore, the increasing awareness of benefits provided by cartilage repair is anticipated to drive the growth of the knee segment.

The major secondary sources associated with the Europe cartilage degeneration market report are the World Health Organization (WHO), British Journal of Sports Medicine, European Society of Sports Traumatology, Knee Surgery, Arthroscopy (ESSKA), Organization for Economic Cooperation and Development (OECD), and others.Read the full report: https://www.reportlinker.com/p05978846/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Go here to read the rest:
Europe Cartilage Degeneration Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Procedure Type ; Application ; and End User and...

VALENCIA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its first quarter 2021 financial results after the market closes on Wednesday, November 11, 2020. In conjunction with such release, the Company plans to host a conference call and webcast that day at 1:30 p.m. Pacific time / 4:30 p.m. Eastern time to discuss its financial results and recent highlights.

Interested parties may access the live call via telephone by dialing (833) 614-1538 for domestic callers or (706) 634-6548 for international callers, using conference ID: 2688929. The live webinar for the call may be accessed by visiting the Events section of the Company's website at ir.avitamedical.com. A replay of the webinar will be available on the Companys website shortly after the conclusion of the call.

Authorized for release by the Chief Executive Officer of AVITA Therapeutics, Inc.

ABOUT AVITA THERAPEUTICS, INC.AVITA Therapeutics is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Therapeutics patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Therapeutics first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018. The RECELL System is indicated for use in the treatment of acute thermal burns in patients 18 years and older. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 8,000 patients globally, reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe.To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTSThis letter includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this letter include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward- looking statement contained in this letter is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this letter. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this letter speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

FOR FURTHER INFORMATION:

See the rest here:
AVITA Therapeutics to Announce First Quarter 2021 Financial Results - GlobeNewswire

A new USC-led study suggests a change to the developmental -- and evolutionary -- story of the pituitary gland.

The pea-sized gland, nestled at the base of the brain, produces hormones that drive growth, aggression, sexual development and reproduction. For decades, the front lobe of the pituitary -- where the hormones are made -- was thought to be an evolutionary development that arose in vertebrates, along with the ear, the nose and the lens of the eye.

The widely accepted "new head hypothesis" holds that all of these body parts derive from a particular type of embryonic structure located in the ectoderm, or outermost layer of an embryo. Meanwhile, animals that have spinal cords but lack backbones, understood to represent an earlier evolutionary step, have a pituitary-like structure previously thought to have a distinct origin in the innermost embryonic layer, or endoderm.

In a paper published today in Science, USC researchers present evidence that, in some vertebrates, the endoderm also forms part of the pituitary's front lobe -- an idea that has been the subject of scientific controversy dating back more than 100 years. Findings from the study, which was supported by a major grant from the National Institutes of Health, suggest that the gland may have a longer evolutionary history than previously thought.

"We revisited very old observations with cutting-edge technology that proves this idea that there is an endodermal contribution to the pituitary," said senior author Gage Crump, professor of stem cell and regenerative medicine at the Keck School of Medicine of USC. "Our work revises ideas about what kind of embryonic structure the pituitary is, and when it first evolved."Developmental detective work

Crump and his colleagues studied zebrafish, a species useful as a lab model in part because their development is an open book to researchers; eggs are fertilized externally and embryos are nearly see-through. The research team used new lab methods of their own invention to label the zebrafish's embryonic cells and follow the cells that descended from them through adulthood.

Additionally, they used time-lapse imaging with a powerful microscope and single-cell RNA sequencing. That latter technology is related to DNA sequencing, but instead of characterizing the entire genetic code, it reveals only the genes that are expressed, and in what quantities, for each of thousands of cells at a time -- a powerful way of understanding the nature of the cells being studied.

In a series of experiments with time-lapse imaging of zebrafish embryos, the team documented Rathke's pouch, a structure from the outer layer previously believed to be the sole source of the pituitary's front lobe, fusing with Seessel's pouch, a structure from the inner layer. Their observations indicate that the endoderm was responsible for about 20 percent of the cells in the front lobe of the pituitary.

Another experiment tracking the fate of embryonic cells into adult zebrafish showed a mixture of ectodermally and endodermally derived cells in the pituitary. Delving into gene expression with RNA sequencing, the scientists found that cells from the inner endoderm layer ended up differentiating into all of the major types of hormone-producing cells in the pituitary. Furthermore, in genetically manipulated zebrafish embryos that lacked the ectodermal component , endodermal cells could form a pituitary-like structure on their own, albeit much smaller than the normal pituitary.

Taken together, these investigations clearly demonstrate an endodermal contribution to the zebrafish pituitary. This unexpected revelation suggests that the quasi-pituitary seen in certain more-primal nonvertebrate animals -- undersea creatures that are strange and largely obscure -- may have survived, in a form, among at least some of their backbone-bearing evolutionary descendants.

Crump, who also is the founding director of USC's PhD Program in Development, Stem Cells, and Regenerative Medicine, cautions that it remains to be seen whether the vestige endures in humans.

"It may be that fish retain this ancestral feature, but humans have lost it," he said. "We can see the pituitary is not a brand-new vertebrate structure like the nose or ear or lens, but instead was already present before vertebrates and subsequently incorporated new ectoderm contributions. By capturing this evolutionary relic in zebrafish, we have resolved the mystery of where the pituitary came from."

An old idea that came back around (surprisingly)

As far back as the mid-1910s, anatomists had reported that Rathke's pouch was closely associated with Seessel's pouch. Rathke's pouch has long been understood as the source of the pituitary's endocrine component. By contrast, the fate and purpose of Seessel's pouch has remained a mystery -- until today.

For researchers in the early 20th century (and more or less ever since), there were no good ways to further explore the relation between the two embryonic structures, and thus the possibility of an endodermal contribution to the pituitary. Hotly debated at first, the topic eventually faded into more of a historical curiosity.

Fortunately, first author Peter Fabian, a postdoctoral researcher at the Keck School, was well-versed in this precedent. While trying out one of those new techniques for labeling and tracking embryonic cells, developed by collaborators at Sanford Burnham Prebys Medical Discovery Institute, he noticed endodermal cells in the pituitary. A light bulb went off in his head.

"It was a serendipitous discovery," Crump said. "We're interested in the endoderm in general, but we hadn't set out to study the pituitary. Because this was such an unexpected observation, we really had to prove it with multiple lines of investigation."

Reference: Fabian P, Tseng KC, Smeeton J, et al.Lineage analysis reveals an endodermal contribution to the vertebrate pituitary.Science. 2020;370(6515)463-467. doi:10.1126/science.aba4767

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the original post:
A New Piece Added to the Pituitary Gland Puzzle Revises Evolutionary History - Technology Networks

The parents of a severely disabled three-year-old boy who needed seven minutes of resuscitation after he was stillborn have appealed for help.

Theo Hutton, from West Kirby, Wirral, needs specialist treatment not available on the NHS - meaning his family need to raise 100,000.

The little boy was put on life support after he was revived, but because he was starved of oxygen, he was subsequently diagnosed with a range of physical and neurological conditions.

These include "floppy baby syndrome", The Liverpool Echo reports.

Theo's mobility is highly restricted and he has been receiving specialised treatment for quadriplegic cerebral palsy not available on the NHS.

This has involved Theo, along with parents Laura and Andy, travelling to the Central American republic of Panama.

Here, Theo has received life-changing stem cell treatment using specialised equipment, including intensive hyperbaric oxygen treatment.

So far the family have made two trips - the last one with just hours to spare to get the last flight out of the country before the borders closed because of coronavirus in March.

But such treatment, along with travelling expenses, doesn't come cheap.

On his JustGiving page, his parents said: "Theo is the biggest fighter we know with every little thing he does being a challenge.

"He has the biggest smile and is the happiest little boy who deserves a chance of the life he was once robbed of.

"There are numerous therapies and pioneering treatments available, but they are not accessible on the NHS and the expense is very high."

Although Theo has benefited massively from the stem cell treatment he has received so far, lockdown means he has not received the intense physio he was due to have for six months until his next course of treatment - which could only go ahead if enough money was raised.

Fundraising events held to raise the huge sums needed have also had to be cancelled because of Covid restrictions.

Theo's aunt, Sally Roberts, who has been directing the fundraising campaign on her nephew's behalf, said: "As an auntie I want to do everything I can to help Theo get the best in life.

Its horrible sitting back during this pandemic and not being able to help.

"My sister and her family decided to go to Panama for stem cell treatment after doing lots of research and speaking to other parents on Facebook who have also visited there.

"Theo has now been for treatment twice in Panama, and both times when he has come home has shown huge changes in his movement and his head core.

His muscle tension has also reduced helping him make more movements.

"I know from speaking to them each day while they were in Panama that it was very traumatic for all of them.

"Theo's last treatment in Panama was in March, luckily he was allowed the full week's treatment but after the last day they stopped letting people in due to Covid, and when they got to the airport to come home they were the last plane out of Panama before they closed their borders."

Sally added: "Without fundraising, his treatments arent possible. Stem cell treatment in Panama costs a minimum of $16,000 each time, and the hyperbaric oxygen chamber costs $17,000.

"None of this can be done through the NHS.

"Due to Theo being so young his brain is still developing, but by the age of five your brain is 90% developed.

"So we want to get as much treatment done as possible before his fifth birthday.

"I understand that times are hard for everyone right now, but even if people cant make a donation, please share the word about Theo and cerebral palsy."

Theo's JustGiving page, which has so far raised nearly 60,000 can be found here: https://www.justgiving.com/campaign/theosfight

There is also a TextGiving code: text THEOSFIGHT 5 to 70085 to donate 5 plus std rate msg.

Alternatively, you can opt to give any whole amount up to 20.

If anyone would like to do a fundraising event for Theo, please message Theosfight@yahoo.com.

Read the rest here:
Boy, 3, who 'died' for seven minutes in race against time to get lifesaving treatment - Mirror Online

An internationalGlobal Exosome Therapeutic Marketreport takes into account key market dynamics including the current market scenario and future prospects of the sector. It also gives the company profile, product specifications, production value, contact information of manufacturer and market shares for company. The statistics are signified in graphical and tabular format for a clear understanding on facts and figures. All the numerical data included in the report is backed up by excellent tools such as SWOT analysis, Porters Five Forces Analysis and others. The report also analyses the emerging trends along with major drivers, challenges and opportunities in theGlobal Exosome Therapeutic Market

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-exosome-therapeutic-market&pm

Exosome therapeutic marketis expected to gain market growth in the forecast period of 2019 to 2026. Data Bridge Market Research analyses that the market is growing with a CAGR of 21.9% in the forecast period of 2019 to 2026 and expected to reach USD 31,691.52 million by 2026 from USD 6,500.00 million in 2018. Increasing prevalence of lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases are the factors for the market growth.

Exosomes are used to transfer RNA, DNA, and proteins to other cells in the body by making alteration in the function of the target cells. Increasing research activities in exosome therapeutic is augmenting the market growth as demand for exosome therapeutic has increased among healthcare professionals.

Increased number of exosome therapeutics as compared to the past few years will accelerate the market growth. Companies are receiving funding for exosome therapeutic research and clinical trials. For instance, In September 2018, EXOCOBIO has raised USD 27 million in its series B funding. The company has raised USD 46 million as series a funding in April 2017. The series B funding will help the company to set up GMP-compliant exosome industrial facilities to enhance production of exosomes to commercialize in cosmetics and pharmaceutical industry.

Increasing demand for anti-aging therapies will also drive the market. Unmet medical needs such as very few therapeutic are approved by the regulatory authority for the treatment in comparison to the demand in global exosome therapeutics market will hamper the market growth market. Availability of various exosome isolation and purification techniques is further creates new opportunities for exosome therapeutics as they will help company in isolation and purification of exosomes from dendritic cells, mesenchymal stem cells, blood, milk, body fluids, saliva, and urine and from others sources. Such policies support exosome therapeutic market growth in the forecast period to 2019-2026.

This exosome therapeutic market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Competitive Landscape and Exosome Therapeutic Market Share Analysis

Global exosome therapeutic market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, concept cars, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companys focus related to global exosome therapeutic market.

The major players covered in the report are evox THERAPEUTICS, EXOCOBIO, Exopharm, AEGLE Therapeutics, United Therapeutics Corporation, Codiak BioSciences, Jazz Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, ReNeuron Group plc, Capricor Therapeutics, Avalon Globocare Corp., CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC., Stem Cells Group among other players domestic and global. Exosome therapeutic market share data is available for Global, North America, Europe, Asia-Pacific, and Latin America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many joint ventures and developments are also initiated by the companies worldwide which are also accelerating the global exosome therapeutic market.

For instance,

Partnership, joint ventures and other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for exosome therapeutics through expanded model range.

Global Exosome Therapeutic Market Scope and Market Size

Global exosome therapeutic market is segmented of the basis of type, source, therapy, transporting capacity, application, route of administration and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Based on type, the market is segmented into natural exosomes and hybrid exosomes. Natural exosomes are dominating in the market because natural exosomes are used in various biological and pathological processes as well as natural exosomes has many advantages such as good biocompatibility and reduced clearance rate compare than hybrid exosomes.

Exosome is an extracellular vesicle which is released from cells, particularly from stem cells. Exosome functions as vehicle for particular proteins and genetic information and other cells. Exosome plays a vital role in the rejuvenation and communication of all the cells in our body while not themselves being cells at all. Research has projected that communication between cells is significant in maintenance of healthy cellular terrain. Chronic disease, age, genetic disorders and environmental factors can affect stem cells communication with other cells and can lead to distribution in the healing process. The growth of the global exosome therapeutic market reflects global and country-wide increase in prevalence of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases, along with increasing demand for anti-aging therapies. Additionally major factors expected to contribute in growth of the global exosome therapeutic market in future are emerging therapeutic value of exosome, availability of various exosome isolation and purification techniques, technological advancements in exosome and rising healthcare infrastructure.

Rising demand of exosome therapeutic across the globe as exosome therapeutic is expected to be one of the most prominent therapies for autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases treatment, according to clinical researches exosomes help to processes regulation within the body during treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases. This factor has increased the research activities in exosome therapeutic development around the world for exosome therapeutic. Hence, this factor is leading the clinician and researches to shift towards exosome therapeutic. In the current scenario the exosome therapeutic are highly used in treatment of autoimmune disease, chronic inflammation, Lyme disease and chronic degenerative diseases and as anti-aging therapy as it Exosomes has proliferation of fibroblast cells which is significant in maintenance of skin elasticity and strength.

For More Insights Get FREE Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-exosome-therapeutic-market&pm

Exosome therapeutic Market Country Level Analysis

The global exosome therapeutic market is analysed and market size information is provided by country by type, source, therapy, transporting capacity, application, route of administration and end user as referenced above.

The countries covered in the exosome therapeutic market report are U.S. and Mexico in North America, Turkey in Europe, South Korea, Australia, Hong Kong in the Asia-Pacific, Argentina, Colombia, Peru, Chile, Ecuador, Venezuela, Panama, Dominican Republic, El Salvador, Paraguay, Costa Rica, Puerto Rico, Nicaragua, Uruguay as part of Latin America.

Country Level Analysis, By Type

North America dominates the exosome therapeutic market as the U.S. is leader in exosome therapeutic manufacturing as well as research activities required for exosome therapeutics. At present time Stem Cells Group holding shares around 60.00%. In addition global exosomes therapeutics manufacturers like EXOCOBIO, evox THERAPEUTICS and others are intensifying their efforts in China. The Europe region is expected to grow with the highest growth rate in the forecast period of 2019 to 2026 because of increasing research activities in exosome therapeutic by population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Huge Investment by Automakers for Exosome Therapeutics and New Technology Penetration

Global exosome therapeutic market also provides you with detailed market analysis for every country growth in pharma industry with exosome therapeutic sales, impact of technological development in exosome therapeutic and changes in regulatory scenarios with their support for the exosome therapeutic market. The data is available for historic period 2010 to 2017.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @[emailprotected]

Original post:
Global Exosome Therapeutic Market Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Business Prospects, In-depth Analysis Research Report...

Note: All notices for events must be emailed to vcarey@delcotimes.com by Thursday at noon. We will not accept faxes or hard copies. All notices will appear online. Print is based on a space-available basis. Thank you.

The Lansdowne Economic Development Corporation (LEDC): is proud to announce it will hold its annual A Bit of the Arts Holiday Fine Art Show and sale at the 20th Century Club (84 S. Lansdowne Avenue, Lansdowne) November 27 from 4-8 p.m. and November 28 from 10 a.m.-4 p.m. This event is FREE to the public.

Veterans Drive-thru: State Rep. Leanne Krueger will host a drive-through veterans appreciation lunch to honor local veterans and share information on resources available to them. Veterans are invited to reserve a spot for the drive-through event, which will be held from 11 a.m.-1 p.m. Oct. 30 at American Legion Post 926, 3220 Concord Road, Aston. As veterans drive through, they will receive a bagged lunch as well as information about benefits and services available for them. The event is free, but RSVP is required. Interested veterans should contact Kruegers office at 610-534-6880 or RepKrueger@pahouse.net to reserve their spot for this event.

The American Helicopter Museum and Education Center: will host author and speaker Kurt Muse November 14, 7-8 p.m., as he recounts his harrowing tale of imprisonment in Panama and daring rescue by the 160th Special Operations Aviation Regiment (SOAR) in 1989. He will speak adjacent AHMECs Hughes MH-6J helicopter, which was recreated from parts of the Little Bird that rescued him. The Museum will stream the event live over Zoom, and a limited number of VIP tickets are available to attend in person, meet Muse, and receive a signed copy of his book, Six Minutes to Freedom. Attendees are asked to make a $20 donation to AHMEC to participate via Zoom. VIP ticket holders are required to donate a minimum of $1000, and abide by the Museums safety precautions, including mask-wearing and social distancing. Attendance onsite will not exceed 30 people and will be subject to cancellation if required by state or local public health mandates. Contact AHMEC at 610-436-9600 or visit http://www.americanhelicopter.museum for more information.

Moms Demand Action Virtual Rally: MomsDadsGrandparents, demand that our politicians step up to the education plate and serve our kids! No one knows better than you that our leaders have failed to adequately support childcare services and Pre-K education programs and have shortchanged K-12 education at every turn during these COVID times. Join the Moms Demand Action Virtual Rally via Zoom Oct 29 at 4 p.m. and demand that Harrisburg and Washington act now. Register at http://bit.ly/MomsRally and prepare to share your challenges and ideas.

The Delaware Art Museum: will present a celebration of essential workers throughout Wilmington with a photography exhibition launching on November 11, 2020, in the Museums Orientation Hallway. The exhibition is set to open on Veterans Day. The Museum is open every Wednesday through Sunday from 10 a.m.-4 p.m. with hours extended to 8 p.m. on Thursdays.

The Delaware County Intermediate Unit: is offering a free workshop to help parents better navigate the often-challenging roadmap of educating their children with disabilities or learning challenges who may need extra help. (The content of this workshop is geared toward parents. There will be no Act 48 or continuing education credit offered if a professional chooses to attend this workshop.) Parents can learn the techniques to help them work with their anxious child, including: 1. What parents need to know about the symptoms and types of anxiety; 2. How to support and talk to your child about anxiety; 3. How to help your child challenge their fears; 4. Strategies to teach your child to manage daily anxiety. November 9, 68 p.m., Via Zoom (Link to be sent via email the morning of the event.), Presenter: Karen Neifer, Professional Development Specialist. There is no cost to attend, but registration is necessary. Register here: HYPERLINK "https://www.eventbrite.com/e/what-parents-can-do-to-help-their-anxious-child-tickets-121247651991"Free Parent Workshop-Anxiety in Children

The Delaware County Intermediate Unit (DCIU) and the Veterans Legacy Project: invite Delaware County students in grades 6-8 to enter the 2020 Veterans Day Essay Contest. The purpose of the contest is to challenge students to think about war and freedom in ways they never have before, to gain a sense of pride in our country and to honor and respect those brave individuals who have risked their lives for our freedom. The first, second and third place winners will receive cash prizes and a certificate and will be invited to read their essays at the Veterans Day Ceremony in Media November 11, at 11:11 a.m. The deadline to submit essay entries is November 4.

Delaware County Women Against Rape (DCWAR): offers free and confidential counseling in person and through our 24-hour hotline to victims of sexual assault. The agency provides medical, police and court accompaniment. DCWAR also facilitates support groups for Adult Survivors of Childhood Sexual Abuse, Adult Survivors of Sexual Assault, and Teen Survivors of Sexual Assault. Educational programs are available to schools, professionals and community groups. Any questions or for services please contact our 24-hour hotline at 610-566-4342.

Delaware County Women Against Rape and Crime Victim Services: offer police/court accompaniment, advocacy and free confidential counseling to victims of serious crimes including robbery, burglary, assault, arson and the surviving family members of homicide victims. Any questions or for services please contact Delaware County Women Against Rape and Crime Victim Services at 610-566-4386.

Ridley High School Class of 1980: Reunion date change: November 13, 2021 - 40th Reunion - Springfield Country Club. Send updated contact information to idleyHighSchool1980@gmail.com. Join our Facebook page RIDLEY HIGH SCHOOL CLASS OF 1980. Discounted hotel rooms available at Courtyard Marriott Springfield if you mention RIDLEY HS CLASS of 1980.

Girls in Science and Technology (GIST): is a fun, educational program that provides girls with hands-on experience in science, technology, engineering, and mathematics (STEM) at the American Helicopter Museum and Education Center. It also provides them with female role models studying and working in STEM disciplines. One-hour online sessions will be held approximately every other Saturday from October 10-March 20. Time: 2-3 p.m. Topics covered: astronomy, physics of flight, energy, chemistry, mechanical engineering, coding and robotics Aimed at: grades 3-8. For more information, see the GIST webpage or contact the Museum at 610-436-9600 or info@americanhelicopter.museum.

Scholarships available: In this time of disruption due to COVID-19, its more important than ever to celebrate young people making a difference through volunteer service. Through November 10, Prudential Financial and the National Association of Secondary School Principals (NASSP) are calling on Pennsylvania youth volunteers to apply for scholarships and national recognition through The Prudential Spirit of Community Awards. Pennsylvania students in grades 5-12 are invited to apply for 2021 Prudential Spirit of Community Awards if they have made meaningful contributions to their communities through volunteering within the past 12 months virtually or otherwise. The application is available at http://spirit.prudential.com.

Eastern State Penitentiary Historic Site: ESPHS has implemented new safety guidelines, including required use of masks, physical distancing, and increased cleaning and sanitization. Visitors will tour the historic site using a modified version of The Voices of Eastern State Audio Tour, the organizations signature program. The audio tour, which is narrated by actor Steve Buscemi and features the voices of former prisoners and correctional staff, will guide visitors on a one-way path through the penitentiary complex. The modified route will include popular points of interest such as Al Capones Cell, Death Row, and the award-winning exhibit Prisons Today: Questions in the Age of Mass Incarceration. Visitors can also watch the 20 animated short films that were created by incarcerated artists for ESPHSs 2019 project Hidden Lives Illuminated. It will be the first time that these films will be screened on site since public screenings on the penitentiarys faade were completed last summer.

Link:
Check out what's happening around town with this week's community calendar - The Delaware County Daily Times

Ongoing studies of Cynata Therapeutics Cymerus stem cell products are beginning to reveal a wide range of commercial possibilities for the ASX-listed companys cutting edge biotechnology that it is looking to apply to a multitude of ailments from the treatment of osteoarthritis and heart attacks through to COVID-19.

In its most advanced trials to date, Cynata will soon embark on a Phase 3 trial of its CYP-004 product, the companys mesenchymal stem cell or MSC product developed to treat osteoarthritis. The 448 person trial is being sponsored by The University of Sydney and will be funded by a project grant from the Australian Government National Health and Medical Research Council.

The company is also progressing on multiple other fronts developing a range of Cymerus MSC therapeutics with the CYP-001 product being another lead candidate. CYP-001 is being developed to treat acute graft-versus-host disease, or GVHD an affliction suffered by bone marrow transplant recipients. GVHD can develop from donated bone marrow that does not take well to a recipients body which triggers an immune response, attacking the host.

Presently, GVHD is treated with steroid therapy however sufferers tend to have a very low survival rate, with less than 20 per cent of patients living for more than two years and few alternate treatment pathways are available.

This looks set to change following Phase 1 trial of Cynatas CYP-001 product on a cohort of patients which saw the survival rate of sufferers of GVHD triple to 60 per cent over a two-year period. The company is now moving CYP-001 into Phase 2 testing and towards commercialisation with partner and shareholder, Fujifilm Corporation.

The matchup with the Japanese-based multi-national is already paying dividends with Cynata receiving an upfront US$3 million payment with further staged payments and royalties to follow in a licensing deal potentially worth more than US$50 million in the longer term.

Stem cells are the building blocks of the human body - essentially the cells from which all other cells are derived and under the right conditions, they can divide to produce more cells sometimes known as Daughter cells. These Daughter cells can become new stem cells or more specialised cells such as blood, bone or even the cells that make up brain or heart tissue.

When appropriately manipulated, stem cells have the potential to treat a range of diseases and aid in the healing and recovery of patients suffering both disease and trauma.

There are a limited number of sources of stem cells - embryonic stem cells, perinatal stem cells and adult stem cells.

Embryonic stem cells are thought to be the most useful and versatile but only harvestable in very small quantities. Perinatal stem cells found in amniotic fluid and umbilical cord blood are also only harvestable in limited quantities although their potential is yet to be fully understood.

Adult stem cells, found in bone marrow or fat, were previously thought to be only useful in producing a limited range of specialised cells with multiple donors required to generate practical amounts of therapeutical medicines.

However, ongoing research shows that by utilising a form of genetic reprogramming, mature cells can be re-programmed to behave like embryonic stem cells. These manipulated cells are called induced pluripotent stem cells, or iPSCs which is where Cynatas Cymerus technology comes into the picture.

Cynatas proprietary Cymerus technology uses iPSCs and a precursor cell called a mesenchymoangioblast to manufacture MSC therapies at a commercial scale without the need for multiple donors. This is where the Cymerus platform diverges from similar therapies, doing away with the need for multiple donors and overcoming a bottleneck in the generation of its product.

Other Cynata MSC products in development include a therapy to assist in the treatment and recovery of heart attacks, which is also showing promise according to the company. Another Cynata product undergoing pre-clinical trials with potential application in the treatment of lung disease is idiopathic pulmonary fibrosis, or IPF. Cynatas research in lung diseases has an unexpected spin-off in that its MSCs may assist in a patients recovery of COVID-19 according to the company. This application is being pursued in a clinical trial in COVID-19 patients presently being conducted in NSW.

These latest results with Cymerus MSCs add to the large body of evidence on the potency of these cells and their potential utility in treating a wide range of devastating diseases. IPF represents an enormous unmet medical need, as existing treatment options have only modest effects on disease progression and survival rates.

Cynatas is now modelling potential MSC therapies to treat various other afflictions too including critical limb ischemia, asthma, sepsis, cytokine release syndrome and diabetic wounds.

In the world of biotechnology, you really only have to produce one winner to attract a longing stare from the big biotechs who can swallow you whole with their massive cheque books with a range of targets and opportunities in its armoury that look to be developing well, dont be surprised if Cynata eventually disappears under the giant footprint of one of the big biotechs.

Is your ASX listed company doing something interesting? Contact: matt.birney@wanews.com.au

View original post here:
Cynata looking to revolutionise stem cell therapy - The West Australian